Alto Neuroscience (ANRO) Share-based Compensation (2023 - 2026)
Alto Neuroscience (ANRO) posted Share-based Compensation of $190000.0 for Q1 2026, up 103.08% sequentially from -$6.2 million in Q4 2025, and down 90.35% YoY from $2.0 million in Q1 2025.
Alto Neuroscience (ANRO) Share-based Compensation (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Share-based Compensation for 4 years, with the latest figure at $190000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 90.35% year-over-year to $190000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.8 million (down 135.31% YoY) and the FY2024 annual result came in at $5.2 million, up 81.46% from the prior year.
- Share-based Compensation rose to $190000.0 in Q1 2026 per ANRO's latest filing, from -$6.2 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.2 million in Q3 2025 and troughed at -$6.2 million in Q4 2025.
- A 4-year average of $693916.7 and a median of $1.2 million in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2026: Share-based Compensation jumped 350.21% in 2024, then plunged 90.35% in 2026.
- Over 4 years, Share-based Compensation stood at $606000.0 in 2023, then jumped by 94.55% to $1.2 million in 2024, then slumped by 622.65% to -$6.2 million in 2025, then jumped by 103.08% to $190000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $190000.0, -$6.2 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 3.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.55 Mn |
| Jun 30, 2026 | 3.55 Mn |
| Mar 31, 2026 | 190,000.00 |
| Mar 31, 2026 | 190,000.00 |
| Dec 31, 2025 | -6.16 Mn |
| Dec 31, 2025 | -6.16 Mn |
| Sep 30, 2025 | 2.19 Mn |
| Sep 30, 2025 | 2.19 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Mar 31, 2025 | 1.97 Mn |
| Mar 31, 2025 | 1.97 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Mar 31, 2024 | 2.18 Mn |
| Mar 31, 2024 | 2.18 Mn |
| Dec 31, 2023 | 606,000.00 |
| Dec 31, 2023 | 606,000.00 |